Login to Your Account



MDRNA Soars on Preclinical Results, Early Pharma Deal

By Jennifer Boggs


Thursday, January 14, 2010
Promising preclinical data with its RNAi-based platform in liver and bladder cancers, combined with an early stage collaboration, sent MDRNA Inc. skyrocketing Wednesday in what could be a sign of news to come from the Bothell, Wash.-based company in 2010. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription